Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06278337 · ClinicalTrials.gov registry record

X-linked Moesin Associated Immunodeficiency

A clinical trial of Infections and Autoimmune Diseases, sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

Recruiting
Registry status
16
Enrollment target
10
Study locations

NCT06278337: Recruiting study of Infections and Autoimmune Diseases, sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

NCT06278337 is a study of Infections and Autoimmune Diseases that is actively recruiting participants, run by Institut National de la Santé Et de la Recherche Médicale, France. The registered enrollment target is 16 participants, below the 3,407-participant average among 26 other Infections trials with a reported enrollment target (100% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06278337, a study of Infections and Autoimmune Diseases, is actively recruiting participants, sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

RECRUITING
Registry status
16 participants
Enrollment target
10
Study locations

Study Summary

Moesin deficiency was initially described in 7 male participants aged 4 to 69 years and is characterized by lymphopenia of the 3 lineages and moderate neutropenia. Genetically, 6 out of 7 participants had the same missense mutation in the moesin gene located on the X chromosome. The 7th patient has a mutation leading to the premature introduction of a STOP codon into the protein.Clinically the 7 participants with X-linked moesin-associated immunodeficiency all presented with recurrent bacterial infections of the respiratory, gastrointestinal or urinary tracts, and some had severe varicella.Therapeutically, in the absence of a molecular diagnosis and due to his SCID-like phenotype, one patient was treated with geno-identical hematopoietic stem cell transplantation . The remaining are untreated or treated with immunoglobulin substitution and/or prophylactic antibiotics. Since this study, the moesin gene has been integrated into DNA chips used for the molecular diagnosis of immune deficiencies in several countries. Physicians in Canada, the United States, Japan, South Africa and Europe have contacted us with a total of 16 known participants to date. Because of their very low severe, uncontrolled CMV infection and the absence of treatment recommendations, two 2 American participants were treated with allogeneic transplantation with severe post-transplant complications (1), and one of the participants died as a result of the transplant. Management of XMAID participants therefore varies widely from country to country, depending on age at diagnosis and clinical picture. It ranges from no treatment treatment (associated with recurrent infections and skin manifestations), IgIv substitution and/or antibiotic prophylaxis antibiotic prophylaxis, with low toxicity and apparent efficacy, and allogeneic transplantation, with all the risks risks involved (graft-related toxicity, graft versus host, disease, rejection, risk of infection). The Investigators therefore feel it is impor

Primary Outcome

The main objective is to study the clinical results of the different therapeutic options applied to X-MAID patients, and to investigate whether there is a correlation between treatment responses and mutation position

Interventions

  • GENETIC genetic restrospective study

Study Locations (10)

Other

  • Genomic Research Centre, School of Biomedical Sciences Institute of Health and Biomedical Innovation - Brisbane
  • Hôpital Universitaire de la Reine Fabiola - Brussels
  • CHU Rennes, CNRS UMR 629 - Rennes
  • CHU St Etienne Hôpital Nord - Saint-Etienne
  • Tokyo Medical and Dental University (TMDU) - Bunkyō City
  • Departments of Internal Medicine and Immunology - Rotterdam

Maryland

  • National Institutes of Health - Bethesda

Pennsylvania

  • Perelman School of medecine - Philadelphia

Rhode Island

  • Brown University - Providence

PARIS

  • Hôpital Necker - Paris

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2021-08-12
Est. Completion 2027-01-12

What NCT06278337 shows while recruiting

NCT06278337 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 3,407-participant average among 26 other Infections trials with a reported enrollment target (100% lower).

The record links to 4 conditions, with Infections appearing as the primary indexed condition, and to 1 intervention - of which genetic restrospective study is the first listed.

NCT06278337 lists 10 locations in 5 states (Other, Maryland, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT06278337 about?

NCT06278337 is a clinical study titled "X-linked Moesin Associated Immunodeficiency". Moesin deficiency was initially described in 7 male participants aged 4 to 69 years and is characterized by lymphopenia of the 3 lineages and moderate neutropenia. Genetically, 6 out of 7 participants had the same missense mutation in the moesin gene located on the X chromosome. The 7th patient has ...

What is the current status of trial NCT06278337?

This trial is currently recruiting. The enrollment target is 16 participants. The study started on 2021-08-12. Estimated completion is 2027-01-12.

What conditions does trial NCT06278337 study?

This clinical trial studies the following conditions: Infections, Autoimmune Diseases, Diagnosis, Immune Deficiency.

What interventions are being tested in trial NCT06278337?

The interventions under investigation include: genetic restrospective study (GENETIC).

Who is sponsoring clinical trial NCT06278337?

This trial is sponsored by Institut National de la Santé Et de la Recherche Médicale, France, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06278337 being conducted?

This trial has 10 study locations across Maryland, Pennsylvania, Rhode Island, PARIS. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06278337's enrollment target sits among peer trials

16 25th of 26 higher than 2 of 26 other Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06278337, the US trial registry maintained by the National Library of Medicine. NCT06278337 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.